Eric M. Dube Sells 18,924 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 18,924 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the transaction, the chief executive officer now directly owns 419,173 shares in the company, valued at $8,823,591.65. The trade was a 4.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded down $0.42 during midday trading on Friday, reaching $20.02. 1,260,658 shares of the company were exchanged, compared to its average volume of 1,534,568. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a fifty day simple moving average of $18.07 and a 200 day simple moving average of $18.82. Travere Therapeutics, Inc. has a 1 year low of $6.01 and a 1 year high of $25.29. The stock has a market cap of $1.78 billion, a P/E ratio of -4.88 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. During the same quarter in the prior year, the business posted ($1.76) earnings per share. Travere Therapeutics's revenue was up 83.3% compared to the same quarter last year. On average, research analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on TVTX. Evercore ISI upped their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Citigroup increased their target price on Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Monday, February 24th. HC Wainwright upped their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, January 15th. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Travere Therapeutics in a report on Friday, May 2nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.79.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Travere Therapeutics during the 4th quarter valued at $31,000. Sterling Capital Management LLC lifted its stake in shares of Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after purchasing an additional 2,115 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth about $53,000. Gen Wealth Partners Inc acquired a new stake in shares of Travere Therapeutics in the fourth quarter valued at about $73,000. Finally, KBC Group NV acquired a new position in Travere Therapeutics during the 1st quarter worth approximately $75,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.